JP2013542226A5 - - Google Patents

Info

Publication number

JP2013542226A5

JP2013542226A5 JP2013536921A JP2013536921A JP2013542226A5 JP 2013542226 A5 JP2013542226 A5 JP 2013542226A5 JP 2013536921 A JP2013536921 A JP 2013536921A JP 2013536921 A JP2013536921 A JP 2013536921A JP 2013542226 A5 JP2013542226 A5 JP 2013542226A5

Authority

JP

Japan

Prior art keywords

composition according

pharmaceutical composition

group

antimicrobial agent

patient

Prior art date

2011-11-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims description 41
• 239000000203 mixture Substances 0.000 claims description 28
• 208000015181 infectious disease Diseases 0.000 claims description 15
• 230000000813 microbial effect Effects 0.000 claims description 15
• 150000001875 compounds Chemical class 0.000 claims description 13
• 239000003937 drug carrier Substances 0.000 claims description 12
• 230000003115 biocidal effect Effects 0.000 claims description 10
• 239000003242 anti bacterial agent Substances 0.000 claims description 9
• 239000004599 antimicrobial Substances 0.000 claims description 9
• 238000004090 dissolution Methods 0.000 claims description 8
• 239000003995 emulsifying agent Substances 0.000 claims description 8
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 7
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
• -1 coatings Substances 0.000 claims description 6
• 230000009089 cytolysis Effects 0.000 claims description 6
• 230000002496 gastric effect Effects 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 229920000642 polymer Polymers 0.000 claims description 6
• AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 claims description 4
• 239000002775 capsule Substances 0.000 claims description 4
• YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical group C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 4
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 4
• 150000002148 esters Chemical class 0.000 claims description 4
• 239000000796 flavoring agent Substances 0.000 claims description 4
• 239000000651 prodrug Substances 0.000 claims description 4
• 229940002612 prodrug Drugs 0.000 claims description 4
• 150000003839 salts Chemical class 0.000 claims description 4
• 239000002904 solvent Substances 0.000 claims description 4
• 229940124307 fluoroquinolone Drugs 0.000 claims description 3
• XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 2
• OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 claims description 2
• OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical group OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 claims description 2
• YSLIPUSJNFIFAB-UHFFFAOYSA-N 2-oxopyridine-1-carboxylic acid Chemical class OC(=O)N1C=CC=CC1=O YSLIPUSJNFIFAB-UHFFFAOYSA-N 0.000 claims description 2
• 108010013198 Daptomycin Proteins 0.000 claims description 2
• 108010015899 Glycopeptides Proteins 0.000 claims description 2
• 102000002068 Glycopeptides Human genes 0.000 claims description 2
• GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
• 241000124008 Mammalia Species 0.000 claims description 2
• 241001465754 Metazoa Species 0.000 claims description 2
• 150000001204 N-oxides Chemical class 0.000 claims description 2
• 108010015795 Streptogramin B Proteins 0.000 claims description 2
• 229940126575 aminoglycoside Drugs 0.000 claims description 2
• 239000003963 antioxidant agent Substances 0.000 claims description 2
• 239000003125 aqueous solvent Substances 0.000 claims description 2
• 239000011230 binding agent Substances 0.000 claims description 2
• 229960005091 chloramphenicol Drugs 0.000 claims description 2
• 238000000576 coating method Methods 0.000 claims description 2
• 239000003086 colorant Substances 0.000 claims description 2
• 230000006835 compression Effects 0.000 claims description 2
• 238000007906 compression Methods 0.000 claims description 2
• 229920001577 copolymer Polymers 0.000 claims description 2
• 229960002488 dalbavancin Drugs 0.000 claims description 2
• 108700009376 dalbavancin Proteins 0.000 claims description 2
• DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims description 2
• 229960005484 daptomycin Drugs 0.000 claims description 2
• 239000007884 disintegrant Substances 0.000 claims description 2
• 239000002270 dispersing agent Substances 0.000 claims description 2
• 239000000945 filler Substances 0.000 claims description 2
• 235000019634 flavors Nutrition 0.000 claims description 2
• 229960003760 florfenicol Drugs 0.000 claims description 2
• 235000013355 food flavoring agent Nutrition 0.000 claims description 2
• 229960003923 gatifloxacin Drugs 0.000 claims description 2
• ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims description 2
• 229960003170 gemifloxacin Drugs 0.000 claims description 2
• 125000005456 glyceride group Chemical group 0.000 claims description 2
• 239000003835 ketolide antibiotic agent Substances 0.000 claims description 2
• 229960003376 levofloxacin Drugs 0.000 claims description 2
• 229960003907 linezolid Drugs 0.000 claims description 2
• TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 2
• 239000000314 lubricant Substances 0.000 claims description 2
• 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
• 229940041033 macrolides Drugs 0.000 claims description 2
• FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 2
• 229960003702 moxifloxacin Drugs 0.000 claims description 2
• VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims description 2
• 229960001607 oritavancin Drugs 0.000 claims description 2
• 108010006945 oritavancin Proteins 0.000 claims description 2
• 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 claims description 2
• 229920000768 polyamine Polymers 0.000 claims description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
• 239000003755 preservative agent Substances 0.000 claims description 2
• YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 claims description 2
• 150000007660 quinolones Chemical class 0.000 claims description 2
• 239000004094 surface-active agent Substances 0.000 claims description 2
• ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims description 2
• 229960005240 telavancin Drugs 0.000 claims description 2
• 108010089019 telavancin Proteins 0.000 claims description 2
• 229920002554 vinyl polymer Polymers 0.000 claims description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
• 239000000080 wetting agent Substances 0.000 claims description 2
• KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 claims description 2
• 150000003952 β-lactams Chemical class 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims 8
• 229940079593 drug Drugs 0.000 claims 8
• 102000016736 Cyclin Human genes 0.000 claims 1
• 108050006400 Cyclin Proteins 0.000 claims 1
• 108010034396 Streptogramins Proteins 0.000 claims 1
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
• 238000009506 drug dissolution testing Methods 0.000 claims 1
• 229910052736 halogen Inorganic materials 0.000 claims 1
• 150000002367 halogens Chemical class 0.000 claims 1
• 229940041030 streptogramins Drugs 0.000 claims 1
• 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
• 238000000034 method Methods 0.000 description 8
• 229940041011 carbapenems Drugs 0.000 description 2
• 238000007922 dissolution test Methods 0.000 description 2
• IBXDWOGXZNFARB-IBGZPJMESA-N CC(NC[C@@H](CN1c2ccc(-c3ccc(CNCCCF)cc3)c(F)c2)OC1=O)=O Chemical compound CC(NC[C@@H](CN1c2ccc(-c3ccc(CNCCCF)cc3)c(F)c2)OC1=O)=O IBXDWOGXZNFARB-IBGZPJMESA-N 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 244000292604 Salvia columbariae Species 0.000 description 1
• 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
• 235000001498 Salvia hispanica Nutrition 0.000 description 1
• 108010015791 Streptogramin A Proteins 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 235000014167 chia Nutrition 0.000 description 1
• 229940041028 lincosamides Drugs 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• DAIKHDNSXMZDCU-FQTGFAPKSA-N pristinamycin IIA Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2 DAIKHDNSXMZDCU-FQTGFAPKSA-N 0.000 description 1
• DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 description 1
• BTTNOGHPGJANSW-IBGZPJMESA-N radezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C1=CC=C(C=2C=CC(CNCC=3NN=NC=3)=CC=2)C(F)=C1 BTTNOGHPGJANSW-IBGZPJMESA-N 0.000 description 1